Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237373 | 0.74 | LMNA (0.33) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30041368 | 0.70 | — | — | |
| SCHEMBL27669050 | 0.65 | — | — | |
| SCHEMBL117813 | 0.65 | — | — | |
| SCHEMBL2221620 | 0.64 | — | — | |
| SCHEMBL22557953 | 0.64 | TSHR (0.32) | TSHR | |
| SCHEMBL29182294 | 0.63 | GAA (0.31) | — | |
| SCHEMBL26980836 | 0.63 | CHRM2 (0.30) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28260676 | 0.63 | — | — | |
| SCHEMBL27691376 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| US-20210070775-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | US | disclosed |
| WO-2021043951-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | WO | disclosed |
| EP-3615544-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2020-03-04 | — | — | EP | disclosed |
| US-10538535-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2020-01-21 | — | — | US | disclosed |
| US-10442820-B2 | — | — | 2019-10-15 | — | — | US | disclosed |
| US-20180312529-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | US | disclosed |
| WO-2018197663-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | WO | disclosed |
| US-9969739-B2 | Tricyclic chiral compounds and their use in asymmetric catalysis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-05-15 | — | — | US | disclosed |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | UNIV NANYANG TECH (SG) | 2016-07-21 | — | — | US | disclosed |
| WO-2010027334-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | LMNA 1898/4885CHRM2 4849/4885CHRM4 4874/4885 |
| US-10538535-B2 | Antitumoral compounds | TP53, RB1, XPOT | LMNA 2420/4885CHRM2 2651/4885CHRM4 2549/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | LMNA 1550/4885CHRM2 4842/4885CHRM4 4844/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | LMNA 1254/4885CHRM2 4323/4885CHRM4 4189/4885 |
| US-20210070775-A1 | Antitumoral Compounds | TP53, RB1, XPOT | LMNA 2420/4885CHRM2 2651/4885CHRM4 2549/4885 |
| US-10442820-B2 | — | RPS4X, RPS4Y1, XPOT | LMNA 2072/4885CHRM2 1053/4885CHRM4 1251/4885 |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | COX6C, CBR3, CYCS | LMNA 2287/4885CHRM2 56/4885CHRM4 32/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | LMNA 1898/4885CHRM2 4849/4885CHRM4 4874/4885 |
| US-20180312529-A1 | Antitumoral Compounds | TP53, RB1, XPOT | LMNA 2420/4885CHRM2 2651/4885CHRM4 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.